Predicting the future in castration-resistant prostate cancer

被引：2
|
作者：
Verhagen, Paul [1 ]
机构：
[1] Erasmus MC, NL-3015 CE Rotterdam, Netherlands
来源：
LANCET ONCOLOGY | 2009年 / 10卷 / 03期
关键词：
SURVIVAL; BENEFIT;
D O I：
10.1016/S1470-2045(09)70049-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：201 / 202
页数：2
相关论文
共 50 条
  • [1] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
  • [2] Predicting prognosis in castration-resistant prostate cancer
    Nature Reviews Cancer, 2012, 12 (11) : 736 - 736
  • [3] PREDICTING BONE SCAN POSITIVITY IN CASTRATION-RESISTANT PROSTATE CANCER
    Moreira, Daniel
    Howard, Lauren
    Sourbeer, Katie
    Kundich, Robert
    Kane, Christopher
    Aronson, William
    Terris, Martha
    Cooperberg, Matthew
    Amling, Christopher
    Freedland, Stephen
    JOURNAL OF UROLOGY, 2014, 191 (04): : E471 - E471
  • [4] Novel approaches and future directions in castration-resistant prostate cancer
    Nabhan, C.
    Parsons, B.
    Touloukian, E. Z.
    Stadler, W. M.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 1948 - 1957
  • [5] Darolutamide For Castration-Resistant Prostate Cancer
    Bastos, Diogo A.
    Antonarakis, Emmanuel S.
    ONCOTARGETS AND THERAPY, 2019, 12 : 8769 - 8777
  • [6] Immunotherapy for Castration-Resistant Prostate Cancer
    Sonpavde, Guru
    Kantoff, Philip W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 465 - +
  • [7] Chemotherapy for castration-resistant prostate cancer
    Berthold, D.
    ONKOLOGIE, 2011, 34 : 12 - 12
  • [8] Strategies in castration-resistant prostate cancer
    Bessede, Th
    PROGRES EN UROLOGIE, 2011, 21 : S68 - S71
  • [9] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [10] Abiraterone and castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2013, 14 (02): : E48 - E48
12345